Quantcast
Home > Quotes > ALDX
ALDX

Aldeyra Therapeutics, Inc. Common Stock (ALDX) Quote & Summary Data

$6.54
*  
0.21
3.11%
Get ALDX Alerts
*Delayed - data as of Jun. 14, 2019  -  Find a broker to begin trading ALDX now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
26.5
Today's High / Low
$ 6.78 / $ 6.3434
Share Volume
482,407
50 Day Avg. Daily Volume
207,271
Previous Close
$ 6.75
52 Week High / Low
$ 16.70 / $ 6.50
Market Cap
179,788,204
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0.8

Intraday Chart

Shares Traded

Share Volume:
482,407
50 Day Avg. Daily Volume:
207,271

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -1.95

Trading Range

The current last sale of $6.54 is 0.62% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 6.78 $ 16.70
 Low: $ 6.3434 $ 6.50

Company Description (as filed with the SEC)

We are a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. Our lead product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease, allergic conjunctivitis, noninfectious anterior uveitis, and Sj√∂gren-Larsson Syndrome. We have additional product candidates in development for proliferative vitreoretinopathy and other retinal diseases, post-transplant lymphoproliferative disease, autoimmune disease, metabolic disease, and cancer. We currently intend to commercialize our products directly or through collaborations. None of our product candidates have been approved for sale in the United States or elsewhere. Immune-mediated diseases are conditions that result from an imbalance of inhibitory and stimulatory factors that regulate the immune system.  ... More ...  



Risk Grade

Where does ALDX fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 6.72
Open Date:
Jun. 14, 2019
Close Price:
$ 6.54
Close Date:
Jun. 14, 2019


Consensus Recommendation

Analyst Info